Cyprodine

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyprodine

What is Cyprodine? Identity and Classification

Property Description
Active Ingredient Cyproheptadine Hydrochloride
Form Tablet, Oral Syrup, Oral Solution
Pharmacological Class First-Generation Antihistamine
Common General Use Relief from allergic conditions; Appetite stimulation
Origin Synthetic

What Type of Medicine is Cyprodine and What is its Active Component?

Cyprodine is a commercial brand name for a medication containing the active ingredient Cyproheptadine Hydrochloride. This compound is classified fundamentally as a first-generation antihistamine, belonging to the piperidine class of drugs. The brand and generic versions are typically supplied as a prescription-only substance in standardized formats to ensure therapeutic consistency.

The active component, Cyproheptadine, is a synthetic, small molecule entity manufactured as a single-ingredient product. Being a first-generation agent, it is chemically distinct from newer, second-generation antihistamines, an attribute that is clinically recognized for contributing to its wider spectrum of biological effects. It is often provided in an oral syrup form specifically to suit patient groups, such as children, who require liquid administration.


How is Cyproheptadine Classified Pharmacologically?

Cyproheptadine is distinguished by its multi-receptor profile, primarily acting as an H1-histaminergic receptor antagonist and a significant antiserotonergic agent. This means it blocks the activity of both Histamine (a key chemical in allergic responses) and Serotonin (a chemical involved in appetite regulation).

The pharmacological classification confirms its dual general purpose: relieving discomfort associated with common allergic conditions and exerting an orexigenic effect (appetite stimulation). This appetite-stimulating feature differentiates it from most other antihistamines, allowing the medicine to provide relief across a range of symptoms, including the management of certain weight-related concerns.


What are the Available Forms of Cyproheptadine?

The medicine is commonly available for systemic use in two primary dosage forms: a solid tablet and a liquid oral syrup or solution. The intended route of administration for all these forms is oral (taken by mouth). The availability of both the solid tablet form and the liquid syrup (which uses an aqueous or sugar-based vehicle) ensures flexibility for various patient groups, promoting a consistent delivery of the active ingredient regardless of age or difficulty swallowing solid medication.

Regulatory References

  1. Cyproheptadine: MedlinePlus Drug Information

What side effects are possible with Cyprodine?

Possible Side Effects and Safety Information

The official regulatory safety profile of Cyprodine (Cyproheptadine Hydrochloride) is classified by the types of adverse reactions documented and their reported frequency. The most common adverse effects documented in official labeling are related to the central nervous system.

Common and Documented Adverse Reactions

The most frequently reported effects, often classified as common, include drowsiness (sedation) and somnolence. Regulatory texts note that this sedation may be transient, with patients often reporting that the effect subsides after the first three to four days of continuous use. Other common effects may include disturbed coordination and dizziness.

Adverse reactions are grouped by System-Organ Class in official prescribing information, including: Nervous System disorders, Gastrointestinal disorders (such as dry mouth, nausea, and weight gain), and Metabolism and Nutrition disorders.

Serious and Population-Specific Safety Statements

Rare, but serious adverse reactions explicitly documented in official sources involve the Blood and Lymphatic System, such as agranulocytosis, leukopenia, and hemolytic anemia, typically associated with prolonged use. Serious effects on the Hepatobiliary System, including jaundice and hepatic failure, have also been documented.

Official safety information contains specific constraints for certain populations. Older adults may be more susceptible to side effects like sedation, dizziness, and hypotension. Children carry a noted risk of paradoxical excitement (e.g., restlessness or irritability). The medicine is contraindicated for newborn and premature infants and is generally advised against for nursing mothers.

Safety Restrictions and Limitations

The medicine is subject to high-level contraindications documented in regulatory labeling, including use in patients with conditions such as narrow-angle glaucoma, stenosing peptic ulcer, or bladder neck obstruction. Use in patients experiencing an acute asthma attack is also contraindicated.

Overdose and Emergency Response

Overdose and When to Seek Help

Cyprodine overdose is officially documented as presenting with a range of serious clinical signs. Manifestations may include a paradoxical combination of Central Nervous System (CNS) depression, such as extreme drowsiness or coma, and CNS stimulation, which can involve agitation, hallucinations, and tremors. Overdose is further characterized by pronounced anticholinergic effects, which result in symptoms like dilated pupils, dry mouth, and an abnormally rapid heart rate (tachycardia).

The regulatory labeling stresses that overdose carries the risk of severe, life-threatening outcomes, including convulsions, respiratory arrest, and cardiac arrest. These severe events necessitate immediate professional intervention. Infants and young children are noted to be particularly susceptible to the CNS stimulatory effects and severe complications of overdose.

Action Mandated by Regulatory Authorities

Immediate medical assistance must be sought at the first suspicion of an overdose. You must contact emergency services or a Poison Control Center immediately. Treatment is defined as symptomatic and supportive. There is no specific antidote listed in the official prescribing information. Supportive measures may include monitoring of vital signs, continuous ECG assessment, and procedures such as gastric lavage and the administration of activated charcoal, as deemed necessary by medical personnel.

Therapeutic Uses of Cyprodine

Quick Facts

  • Relief of Allergic Symptoms: May offer relief from perennial and seasonal allergic rhinitis.
  • Skin Manifestations: May assist in managing certain allergic skin issues, such as uncomplicated urticaria (hives) and angioedema.
  • Conjunctivitis: May be used to address allergic conjunctivitis caused by inhalant allergens and certain foods.
  • Vasomotor Rhinitis: Used in the management of non-allergic rhinitis.

Cyprodine is an agent that may be indicated for addressing various manifestations of allergic conditions. The medication is used for the management of perennial and seasonal allergic rhinitis, which may include symptoms related to hay fever and other inhalant allergens.

Furthermore, Cyprodine may assist in managing certain allergic skin presentations, such as mild, uncomplicated urticaria and angioedema, as well as dermatographism. It is also utilized for allergic conjunctivitis resulting from inhalant allergens and food exposure. In specific clinical contexts, Cyprodine is intended for use as adjunctive therapy in managing anaphylactic reactions after acute manifestations have been controlled with standard measures, such as epinephrine.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cyprodine?

The population eligibility for Cyproheptadine is strictly defined by regulatory authorities and is based on age, physiological status, and the presence of specific comorbidities.

Contraindicated Populations (Must Not Use)

Cyprodine is contraindicated (absolutely prohibited) in several groups due to documented risks, including newborn or premature infants, nursing mothers, and debilitated elderly patients. Use is also forbidden for patients with known conditions such as angle-closure glaucoma, stenosing peptic ulcer, bladder neck obstruction, or those concurrently taking MAO inhibitor therapy.


Eligibility and Restriction Rules

Category Regulatory Status
Pediatric Use Approved for children mathbfge 2 years of age; safety is not established for those under 2.
Pregnancy Status Category B; permitted only if clearly needed by the physician.
Organ Impairment Use requires caution in patients with hepatic impairment or renal insufficiency.
Geriatric Patients Dose selection must be cautious; the debilitated subset is contraindicated.
Comorbidities Use requires caution in patients with a history of bronchial asthma, hyperthyroidism, or cardiovascular disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cyprodine (Cyproheptadine Hydrochloride) based on several documented substance classes and specific physiological constraints.

Documented Interaction Restrictions

Category Official Regulatory Statement
Contraindicated Combinations Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is prohibited as MAOIs prolong and intensify the drug’s anticholinergic effects.
Additive Effects Use with alcohol and other Central Nervous System (CNS) depressants (e.g., sedatives, tranquilizers) produces additive effects resulting in increased CNS depression.
Pharmacodynamic Antagonism Cyprodine may interfere with the intended effects of serotonin-enhancing antidepressants, potentially leading to a recurrence of related symptoms.

Specific Interaction Constraints

The most severe interaction constraint is the contraindication with MAOIs, which is an absolute restriction on co-administration. Interactions with CNS depressants and alcohol are categorized as clinically significant due to the resultant additive sedative action. A population-specific consideration exists for patients with renal insufficiency, where the drug's elimination is diminished, a constraint noted in labeling that alters expected drug exposure. The documentation strictly details these patterns and constraints without offering clinical recommendations or prescribing instructions.

Mechanism of Action

How Cyprodine Works

Cyprodine (Cyproheptadine) exerts its pharmacodynamic effects primarily through competitive antagonism at multiple targets, notably the H1 Histamine receptors and specific 5-HT 2A/2C Serotonin receptors. In peripheral tissues, H1 receptor blockade modulates the signaling that drives vascular permeability and nerve stimulation. Centrally, the antagonism of 5-HT receptors, particularly in the hypothalamus, removes inhibitory signaling, thereby influencing the central neural circuits that govern energy intake. The broad, non-selective nature of the mechanism means these primary actions are accompanied by effects on other regulatory pathways, including the Muscarinic Acetylcholine ( M) receptors. Antagonism at M receptors interferes with cholinergic signaling, resulting in reduced glandular secretions. Furthermore, H1 antagonism within the Central Nervous System leads to a modulation of the histaminergic neural pathways that influence alertness. This multi-receptor binding profile dictates the full physiological effect.

Dosage and Administration Information

The use of Cyprodine (Cyproheptadine Hydrochloride) involves specific parameters concerning route, dosage, frequency, and patient populations.

The established route of administration for all formulations is oral. The medication is available as a 4 mg tablet and an oral solution/syrup typically containing 2 mg per 5 mL.

Dosing is individualized based on the patient’s response and size. For adults, the initial dose is generally 4 mg three times a day (TID). The total daily dose often falls between 4 mg and 20 mg, administered in divided doses to ensure continuous effect, as the effect of a single dose lasts approximately four to six hours. The maximum recommended adult daily dose is not to exceed 0.5 mg/kg/day. The medicine may be administered without regard to meals.


Dosing Instructions for Specific Populations

Population Administration Parameters
Pediatric (7 to 14 years) Maximum daily dose is 16 mg.
Pediatric (2 to 6 years) Maximum daily dose is 12 mg or approximately 0.25 mg/kg/day.
Older Adults & Renal/Hepatic Impairment Dose selection requires caution and is typically initiated at the low end of the therapeutic range. Lower doses are utilized for those with renal insufficiency.

This framework emphasizes the practice of dividing the daily dosage and applying specific limits across different age groups and clinical contexts to maintain consistent therapeutic levels.

Recent Clinical Evidence

Evidence for Use in Allergic Conditions

Research concerning Cyprodine for allergic conditions consists primarily of original clinical trials and controlled studies conducted several decades ago that were reviewed for regulatory authorization. These studies examined how symptoms change over time in patients with fluctuating manifestations like hay fever and hives, monitoring changes in acute allergic symptoms and objective skin changes. Findings from this foundational evidence base support the drug's long-standing regulatory authorization for these uses. However, there is limited recent, large-scale randomized controlled trials (RCTs) comparing this medicine to newer agents, and further comparative evidence is lacking.

Evidence for Appetite Stimulation and Weight Gain

Research examined Cyprodine in the context of weight and appetite, including both older observational studies and more recent randomized, double-blind, placebo-controlled trials (RCTs). These studies explored short-term symptom changes in populations, including underweight children and adults with poor appetite. Researchers primarily monitored objective changes in body weight, BMI, and patient-reported appetite scores. Trials data show patterns related to body weight in groups receiving Cyprodine compared to those receiving a placebo in short-term periods (e.g., 8–12 weeks).

Research Gaps and Unanswered Questions

Certainty regarding the long-term status of the weight change appears low, as follow-up durations were limited in many primary studies. Research in specialized pediatric sub-groups often involved small sample sizes (N), and methodological heterogeneity exists in how appetite improvement was measured. Data for older adults and individuals with complex coexisting health conditions remain limited, and overall, research exploring extended physiological outcomes is not well-developed.

Key Studies & References

  1. Cyproheptadine Drug Information (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Cyprodine (FAQ)

Q: Does Cyprodine cause changes in appetite?

A: Studies and official information indicate that Cyprodine has an orexigenic effect, which means it can stimulate appetite. Due to this action, weight gain is also noted as a documented adverse reaction in official safety information.

Q: What are the most commonly reported side effects of Cyprodine?

A: The most frequently reported effects in regulatory texts are related to the central nervous system. These commonly include drowsiness (sedation), somnolence, disturbed coordination, and dizziness.

Q: Is it normal to feel a bit sleepy when starting Cyprodine?

A: Drowsiness (sedation) and somnolence are documented as common adverse reactions in official labeling. Regulatory texts note that this sedation may be transient, meaning the effect may subside after the first few days of continuous use.

Q: Why does Cyprodine sometimes need to be taken with food?

A: Official administration instructions state the medicine may be taken without regard to meals (with or without food). Its labeling does not describe a regulatory requirement for taking it with food.

Q: Does Cyprodine interact with common medications for depression or anxiety?

A: Official information defines several interaction constraints. Cyprodine is prohibited (contraindicated) with MAO inhibitors. It also has documented additive effects with other Central Nervous System (CNS) depressants, which can include tranquilizers, and it may interfere with the intended effects of some serotonin-enhancing antidepressants.

Q: How long does it usually take to feel the effects of Cyprodine?

A: Pharmacokinetic data from regulatory sources, which describe how the body processes the drug, indicate that Cyprodine typically reaches its peak concentration in the bloodstream approximately 6 to 9 hours after an oral dose.

Q: Is Cyprodine the same as other medicines for the same condition?

A: Cyprodine is classified as a first-generation antihistamine, which makes it chemically different from newer agents used for similar purposes. It is further distinguished by its multi-receptor profile, which includes a notable antiserotonergic action in addition to blocking histamine.

Q: Do I have to take Cyprodine every day, or just when I need it?

A: Official dosing guidelines describe a total daily dose that is administered in divided doses (for example, three times a day) to maintain a continuous therapeutic effect.

Q: Are there any food or drinks I should avoid while using Cyprodine?

A: Official regulatory warnings address consuming alcohol while using Cyprodine. This is because combining the two can produce additive effects that increase central nervous system depression.

Q: Is Cyprodine generally considered a long-term or short-term treatment?

A: Regulatory documents do not set a specific limit on the duration of use. However, evidence summaries note that clinical trials exploring extended physiological outcomes for certain uses are limited, with many primary studies focusing on short-term periods.

Q: What clinical trials or studies support the use of Cyprodine?

A: Authorization for the relief of allergic conditions is based on original clinical trials and controlled studies reviewed by regulatory agencies. Its use for appetite stimulation is supported by specific trials that measured changes in body weight and patient appetite scores in groups receiving the drug compared to a placebo.

Q: Can Cyprodine affect sleep patterns?

A: Yes, as a Central Nervous System (CNS) depressant, somnolence (drowsiness) is a common side effect. Studies have also investigated its pharmacological effects on sleep stages, noting that it may increase slow-wave sleep and decrease REM sleep.

Q: Does Cyprodine have an effect on blood pressure?

A: Official warnings note that hypotension (low blood pressure) is a possible side effect, particularly in older patients. The drug is also listed with specific constraints for patients with pre-existing cardiovascular disease or hypertension (high blood pressure).

Q: Is there a generic version of Cyprodine available?

A: Yes, Cyprodine is the brand name for the generic drug Cyproheptadine Hydrochloride. The active component is available in both brand and generic forms that must meet the same regulatory standards for quality and consistency.

Q: Is Cyprodine known to cause weight gain?

A: Yes, official documentation lists weight gain as a documented adverse reaction, classifying it under Metabolism and Nutrition disorders. This effect is thought to be related to its established property as an appetite stimulant.

Q: How long does Cyprodine stay in your system after stopping?

A: Pharmacokinetic data suggests that the elimination half-life of Cyprodine, which is the time it takes for the concentration of the drug to decrease by half, typically ranges between approximately 8 and 20 hours.

Q: What are the common misunderstandings about Cyprodine's purpose?

A: A common point of focus is the drug's classification. While it is a first-generation antihistamine, unlike newer versions, it also has a significant action that blocks Serotonin (antiserotonergic). This dual action is linked to its established use for both allergic relief and appetite stimulation.

Q: Is Cyprodine a controlled substance?

A: No, official regulatory product information typically indicates that Cyprodine is not classified as a scheduled drug by the DEA (Drug Enforcement Administration). It is a prescription-only medication.

Q: Are there any differences between the brand name and generic Cyprodine?

A: Generic and brand-name versions contain the identical active ingredient and are subject to regulatory standards that ensure bioequivalence. This means they are expected to be absorbed at the same rate and extent and produce the same intended effects.

Q: How quickly does the risk of side effects typically appear after starting Cyprodine?

A: For the common effect of sedation (drowsiness), regulatory texts indicate that this effect may be transient, with patients often reporting that it subsides after the first three to four days of continuous use.

Q: Can Cyprodine be crushed or split if the tablets are large?

A: Official drug product information describes the tablet form as being scored (having a line to separate it into halves). The presence of scoring typically indicates the tablet can be divided along that line.

Q: How does Cyprodine compare to older medications for the same use?

A: Official evidence summaries note that there is limited recent, large-scale randomized controlled trials (RCTs) comparing this medicine to newer agents. The evidence base supporting its use is primarily from foundational studies conducted several decades ago.

Q: What is the official safety classification of Cyprodine for pregnant people?

A: Cyprodine is designated as Pregnancy Category B. This classification means animal reproduction studies have generally not shown evidence of harm to the fetus. Official guidance states that it should be used during pregnancy only if clearly needed.

Q: Can Cyprodine cause changes in mood or anxiety levels?

A: The drug acts as a Central Nervous System (CNS) depressant which can affect mental alertness. Additionally, regulatory warnings note a risk of paradoxical excitement (e.g., restlessness or irritability) in children.

Q: What is the typical duration of treatment with Cyprodine?

A: Official documents do not specify a required duration of treatment. Research summaries note that clinical trials exploring extended physiological outcomes for the use of Cyprodine are limited.

Q: Are there any restrictions on driving or operating machinery while taking Cyprodine?

A: Due to the potential for dizziness and sedation, regulatory warnings address engaging in activities that require mental alertness and motor coordination, such as driving a car or operating machinery.

Q: Is Cyprodine available over the counter in any country?

A: In the United States, official regulatory product information designates Cyprodine as a prescription-only medication.

Q: Does Cyprodine affect how other medicines are absorbed?

A: Official labeling primarily focuses on interactions related to the Central Nervous System effects and the drug’s anticholinergic activity. Regulatory documents do not specifically detail a general impact on the absorption of other medicines.

Q: Are there any long-term health concerns associated with Cyprodine use?

A: Serious adverse reactions explicitly documented in official sources involve the Blood and Lymphatic System and the Hepatobiliary System (liver), which are typically associated with prolonged use. Also, long-term studies regarding cancer risk have not been performed.

Q: How often is Cyprodine typically taken per day?

A: For adults, the suggested dosing initiation is typically three times a day (TID). The total daily dose is administered in divided doses to ensure continuous effect throughout the day.

Q: Is there a specific time of day that is better for taking Cyprodine?

A: Official documents state the medication may be taken at any time without regard to meals. Since common side effects include drowsiness/sedation, this factor is often considered when determining the administration schedule.

Q: What are the documented effects of Cyprodine on a developing fetus or nursing infant?

A: For the fetus, Cyprodine is Category B, meaning animal studies have not shown harm. For nursing infants, it is not known if the drug is excreted in human milk, and official guidance addresses the potential for serious adverse reactions in the infant and states a decision should be made to discontinue nursing or discontinue the drug.

Q: What does 'bioavailability' mean for a drug like Cyprodine?

A: Bioavailability is a term used in pharmacology to define the rate and fraction of an administered drug dose that successfully reaches the systemic circulation (the bloodstream) unaltered. For Cyprodine, pharmacokinetic data indicates its bioavailability is approximately 20-40%.

How should Cyprodine be stored and disposed of?

The storage and disposal of Cyprodine (Cyproheptadine Hydrochloride) must follow the exact conditions specified in its official regulatory labeling to ensure product stability and safety.

Storage Conditions and Container

  • Store the medication at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). Temporary temperature excursions are permitted between 15 C and 30 C (59 F and 86 F).
  • The medication must be kept in its original container, tightly closed, and stored away from excess heat, moisture, and light.
  • To prevent accidental ingestion, the packaging must utilize a child-resistant closure (as required), and the product must be kept out of the reach of children.

Disposal Instructions

  • Outdated or no longer needed medicine should not be kept.
  • The official disposal guidance instructs individuals to seek advice from a healthcare professional on how to safely dispose of any unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cyprodine found in:

A-Z Index: